Novo Nordisk scales manufacturing

Novo Nordisk is spending heavily to do something it could not do two years ago: sell obesity drugs as if they were normal medicines, not scarce luxury goods. The company has been racing to add capacity across its network after demand for Wegovy and Ozempic repeatedly outran supply. In its 2024 annual report, Novo said it had invested more than 80 billion Danish kroner in new active pharmaceutical ingredient facilities, centered in places like Kalundborg, Denmark, to make more of the drug substance itself rather than depend as much on outside partners (novonordisk.com). That shift matters because the bottleneck was never just demand. It was the factory floor. So Novo is widening the floor. In April 2025, the company announced an 8 billion kroner expansion of its Montes Claros site in Brazil, adding aseptic production, warehousing, and a new quality-control lab to boost output of injectable treatments, including GLP-1 products, with construction expected to run through 2028 (novonordisk.com). In the U.S., it is building a new $4.1 billion aseptic manufacturing and finished-production facility in Clayton, North Carolina, the largest life-science investment in that state’s history, on top of earlier expansions there (novonordisk-us.com). Novo’s own U.S. materials say the company has already expanded repeatedly in North Carolina and is adding another 1,000 jobs as it grows that footprint (novonordisk-us.com). The company is also buying speed where it can. After Novo Holdings completed its acquisition of Catalent in late 2024, Novo Nordisk took control of three fill-finish sites in Italy, Belgium, and Bloomington, Indiana. Those are the plants that turn bulk drug into pens and finished injectable products. Novo has said the deal expands its global fill-finish footprint from 11 sites to 14, which is a blunt admission of where the pain was: not only in making semaglutide, but in packaging it at scale (catalent.com, pharmamanufacturing.com). That manufacturing push has started to change the market. On February 21, 2025, the FDA formally determined that the semaglutide injection shortage covering Wegovy and Ozempic was resolved, saying supply now met or exceeded current and projected U.S. demand (fda.gov). Novo’s own annual report described its production network as operating around the clock and framed the factory build-out as a way to improve supply stability, not just chase growth (annualreport.novonordisk.com, novonordisk.com). That is the real story here. Novo is trying to turn a shortage-era blockbuster into an industrial product. You can see the strategy in how it launched Wegovy HD. The higher-dose 7.2 mg version won FDA approval on March 19, 2026, after a trial in adults with obesity showed about 20.7% average weight loss at 72 weeks if patients stayed on treatment, versus 17.5% on the 2.4 mg dose (prnewswire.com). Less than three weeks later, Novo said Wegovy HD was available nationwide through more than 70,000 U.S. pharmacies, NovoCare Pharmacy, and selected telehealth providers (prnewswire.com). That is what scaled manufacturing looks like in practice: a new dose, a wide launch, and enough pens on shelves that the company can act like supply is finally part of the product.